The DOI matches its Crossref record; 113 of the 116 references it cites were found in a registry or an index.
Blockade of the angiotensin system improves mental health domain of quality of life: A meta-analysis of randomized clinical trials
Open accessAbstract
Objective: It is unclear whether blockade of the angiotensin system has effects on mental health. Our objective was to determine the impact of angiotensin converting enzyme inhibitors and angiotensin II type 1 receptor (AT1R) blockers on mental health domain of quality of life. Study design: Meta-analysis of published literature. Data sources: PubMed and clinicaltrials.gov databases. The last search was conducted in January 2017. Study selection: Randomized controlled trials comparing any angiotensin converting enzyme inhibitor or AT1R blocker versus placebo or non-angiotensin converting enzyme inhibitor or non-AT1R blocker were selected. Study participants were adults without any major physical symptoms. We adhered to meta-analysis reporting methods as per PRISMA and the Cochrane Collaboration. Data synthesis: Eleven studies were included in the analysis. When compared with placebo or other antihypertensive medications, AT1R blockers and angiotensin converting enzyme inhibitors were associated with improved overall quality of life (standard mean difference = 0.11, 95% confidence interval = [0.08, 0.14], p < 0.0001), positive wellbeing (standard mean difference = 0.11, 95% confidence interval = [0.05, 0.17], p < 0.0001), mental (standard mean difference = 0.15, 95% confidence interval = [0.06, 0.25], p < 0.0001), and anxiety (standard mean difference = 0.08, 95% confidence interval = [0.01, 0.16], p < 0.0001) domains of QoL. No significant difference was found for the depression domain (standard mean difference = 0.05, 95% confidence interval = [0.02, 0.12], p = 0.15). Conclusions: Use of angiotensin blockers and inhibitors for the treatment of hypertension in otherwise healthy adults is associated with improved mental health domains of quality of life. Mental health quality of life was a secondary outcome in the included studies. Research specifically designed to analyse the usefulness of drugs that block the angiotensin system is necessary to properly evaluate this novel psychiatric target.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Lithium and divalproex are also associated with weight gain.791”
Citations
Cites
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722 · cited 2×
“We analysed the funnel plot graph for verifying publication bias, which is a scatter plot of the SMD against a measure of study size, calculated the Egger test (Egger et al., 1997; Soeken and Sripusanapan, 2003) and employed the Orwin’s fail-safe N test to quantify the number of possible negative omitted studies that…”
Method(1992) · PubMed · Cited by 33,716
The MOS 36-ltem Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection
Ware, J. E., & Sherbourne, C. D. (1992) · Medical Care · doi:10.1097/00005650-199206000-00002 · Cited by 30,033
Vos, T., Barber, R. M., Bell, B., Bertozzi-Villa, A., Biryukov, S., Bolliger, I., Charlson, F., Davis, A., Degenhardt, L., Dicker, D., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60692-4 · Cited by 6,414
McHorney, C. A., Ware, J. E., Rachel Lu, J. F., & Sherbourne, C. D. (1994) · Medical Care · doi:10.1097/00005650-199401000-00004 · Cited by 4,458
Kushner (2021) · doi:10.12788/jfp · Cited by 3,799
Quantitative Synthesis in Systematic Reviews
Lau, J., Ioannidis, J. P. A., & Schmid, C. H. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-127-9-199711010-00008 · Cited by 2,517
Imputing missing standard deviations in meta-analyses can provide accurate results
Furukawa, T. A., Barbui, C., Cipriani, A., Brambilla, P., & Watanabe, N. (2006) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2005.06.006 · Cited by 1,568 · cited 1×
“For trials that did not report SD or other dispersion measure, the SD of similar trials was imputed to ensure standardizing constants were comparable across trials as per the method of Furukawa (Furukawa et al., 2006).”
MethodAndrews, J., Guyatt, G., Oxman, A. D., Alderson, P., Dahm, P., Falck-Ytter, Y., Nasser, M., Meerpohl, J., Post, P. N., Kunz, R., et al. (2013) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2012.03.013 · Cited by 1,416 · cited 1×
“The evidence was assessed and ranked according to the grading of recommendations assessment, development and evaluation (GRADE) for high risk of bias, imprecision, indirectness, heterogeneity and publication bias (Andrews et al., 2013).”
MethodThe Effects of Antihypertensive Therapy on the Quality of Life
Croog, S. H., Levine, S., Testa, M. A., Brown, B., Bulpitt, C. J., Jenkins, C. D., Klerman, G. L., & Williams, G. H. (1986) · New England Journal of Medicine · doi:10.1056/nejm198606263142602 · Cited by 1,325 · cited 2×
“Twenty studies did not use a validated scale for measuring QoL and were hence excluded (Bracchetti et al., 1990; Conlin et al., 1998; Croog et al., 1986; Ebert and Kirch, 1999; Fagher et al., 1991; Fletcher et al., 1992; Freytag et al., 2001; Hu and Zhu, 1999; Lacourciere, 1988; Lewis et al., 1996; McMahon et al., 199…”
MethodRusso, J., Trujillo, C. A., Wingerson, D., Decker, K., Ries, R., Wetzler, H., & Roy-Byrne, P. (1998) · Medical Care · doi:10.1097/00005650-199805000-00015 · Cited by 1,308 · cited 2×
“The SF-36 has been documented as both valid and reliable (Mchorney et al., 1994; Russo et al., 1998), and was used in two studies (Kusek et al.”
MethodBerk, M., Kapczinski, F., Andreazza, A. C., Dean, O. M., Giorlando, F., Maes, M., Yücel, M., Gama, C. S., Dodd, S., Dean, B., et al. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.10.001 · Cited by 1,178
Self-citationNeaton, J. D. (1993) · JAMA · doi:10.1001/jama.270.6.713 · Cited by 946 · cited 1×
“…Fagher et al., 1991; Fletcher et al., 1992; Freytag et al., 2001; Hu and Zhu, 1999; Lacourciere, 1988; Lewis et al., 1996; McMahon et al., 1990; Neaton et al., 1993; Oparil et al., 1996; Paran et al., 1996; Perry et al., 1994; Tanser et al., 2000; Tedesco et al., 1999; Testa et al., 1993; Weir…”
(1973) · New England Journal of Medicine · doi:10.1056/nejm197307122890231 · Cited by 895
Kessler, R. C. (2012) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2011.11.005 · Cited by 871 · cited 1×
“Remission of symptoms may present formidable difficulties, and full remission is only achieved by a small population of persons and usually after several courses of treatment (Global Burden and Disease Study, 2015; Kessler, 2012).”
BackgroundVascular Health and Risk Management
(2020) · Vascular Health and Risk Management · doi:10.2147/vhrm · Cited by 700
Bowden, J., Tierney, J. F., Copas, A. J., & Burdett, S. (2011) · BMC Medical Research Methodology · doi:10.1186/1471-2288-11-41 · Cited by 553 · cited 1×
“Inconsistency across studies was evaluated using the I2 metric, which describes the percentage of the variability in effect estimates that is due to heterogeneity rather than sampling error(Higgins and Green, 2011) and is considered substantial when greater than 50% (Bowden et al., 2011).”
MethodThe new field of ‘precision psychiatry’
Fernandes, B. S., Williams, L. M., Steiner, J., Leboyer, M., Carvalho, A. F., & Berk, M. (2017) · BMC Medicine · doi:10.1186/s12916-017-0849-x · Cited by 549
Self-citationLi, N.-C., Lee, A., Whitmer, R. A., Kivipelto, M., Lawler, E., Kazis, L. E., & Wolozin, B. (2010) · BMJ · doi:10.1136/bmj.b5465 · Cited by 486 · cited 2×
“…decrease neuroinflammation by decreasing angiotensin II activity and have therefore been proposed as novel therapeutic targets for inflammatory brain diseases as well as for cognitive disorders (Benicky et al., 2011; Borrajo et al., 2014; De Souza et al., 2015, Kume et al., 2012; Li et al., 2010).”
BackgroundMethodSchmacke, N. (2024) · Vertrauen in die Medizin · doi:10.30820/9783837961249-13 · Cited by 465
(2019) · Journal of Human Hypertension · doi:10.1038/41371.1476-5527 · Cited by 389
A self-rating scale of distress
Kellner, R., & Sheffield, B. F. (1973) · Psychological Medicine · doi:10.1017/s0033291700046377 · Cited by 281
Quality of Life and Antihypertensive Therapy in Men -- A Comparison of Captopril with Enalapril
Testa, M. A., Anderson, R. B., Nackley, J. F., & Hollenberg, N. K. (1993) · New England Journal of Medicine · doi:10.1056/nejm199304013281302 · Cited by 264 · cited 1×
“…al., 1992; Freytag et al., 2001; Hu and Zhu, 1999; Lacourciere, 1988; Lewis et al., 1996; McMahon et al., 1990; Neaton et al., 1993; Oparil et al., 1996; Paran et al., 1996; Perry et al., 1994; Tanser et al., 2000; Tedesco et al., 1999; Testa et al., 1993; Weir et al., 1996a; Yodfat et al., 1985).”
Angiotensin II AT1 Receptor Blockade Ameliorates Brain Inflammation
Benicky, J., Sánchez-Lemus, E., Honda, M., Pang, T., Orecna, M., Wang, J., Leng, Y., Chuang, D.-M., & Saavedra, J. M. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2010.225 · Cited by 254 · cited 5×
“Drugs that decrease angiotensin II activity have pleiotropic mechanisms of action that suggest potential efficacy as novel psychotropic agents for neuropsychiatric disorders (Benicky et al., 2011; Borrajo et al., 2014; De Souza et al., 2015; Kume et al., 2012; Li et al., 2010) and neuroprotection (Cernes et al.”
BackgroundMethodInfluentialCognitive remission: a novel objective for the treatment of major depression?
Bortolato, B., Miskowiak, K. W., Köhler, C. A., Maes, M., Fernandes, B. S., Berk, M., & Carvalho, A. F. (2016) · BMC Medicine · doi:10.1186/s12916-016-0560-3 · Cited by 252 · cited 1×
“Drugs that act on the angiotensin system, such as the antihypertensives angiotensin I converting enzyme (ACE) inhibitors and angiotensin II type 1 receptor (AT1R) blockers, have been suggested to possess antidepressive properties (Bortolato et al., 2016; Ping et al., 2014).”
BackgroundSelf-citationScandinavian Journal of Primary Health Care
(1983) · Scandinavian Journal of Primary Health Care · doi:10.3109/02813438309038459 · Cited by 242
Na, K.-S., Lee, K. J., Lee, J. S., Cho, Y. S., & Jung, H.-Y. (2014) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2013.09.006 · Cited by 176 · cited 2×
“, 2016), celecoxib (Na et al., 2014) and N-acetyl-cysteine (NAC) (Fernandes et al.”
Tibblin, G., Tibblin, B., Peciva, S., Kullman, S., & Svärdsudd, K. (1990) · PubMed · Cited by 164
(2023) · Polski Merkuriusz Lekarski · doi:10.36740/merkur · Cited by 154
TEDESCO, M. (1999) · American Journal of Hypertension · doi:10.1016/s0895-7061(99)00156-9 · Cited by 142 · cited 2×
“…al., 1992; Freytag et al., 2001; Hu and Zhu, 1999; Lacourciere, 1988; Lewis et al., 1996; McMahon et al., 1990; Neaton et al., 1993; Oparil et al., 1996; Paran et al., 1996; Perry et al., 1994; Tanser et al., 2000; Tedesco et al., 1999; Testa et al., 1993; Weir et al., 1996a; Yodfat et al., 1985).”
Evaluation of quality of life in clinical trials
Wiklund, I. E., & KARLBERG, J. P. E. (1991) · Controlled Clinical Trials · doi:10.1016/s0197-2456(05)80024-8 · Cited by 141 · cited 2×
“…Dahlof et al., 1997, 2005; Omvik et al., 1993; Rake et al., 2001; Rasmussen et al., 2006; Steiner et al., 1990), is designed to assess six domains to determine quality of life: anxiety, depressed mood, positive well-being, self-control, general health and vitality (Wiklund and Karlberg, 1991).”
BackgroundBoal, A., Smıth, D. J., McCallum, L., Muir, S. W., Touyz, R. M., Dominiczak, A. F., & Padmanabhan, S. (2016) · Hypertension · doi:10.1161/hypertensionaha.116.08188 · Cited by 130 · cited 1×
“These results were replicated in another study by Boal et al. (2016) which examined mood related hospital admissions of 144,660 patients treated with antihypertensive monotherapy for a five-year follow-up.”
Result(2018) · Terapevticheskii arkhiv · doi:10.26442/terarkh · Cited by 127
Carvalho, A. F., Berk, M., Hyphantis, T. N., & McIntyre, R. S. (2014) · Psychotherapy and Psychosomatics · doi:10.1159/000357500 · Cited by 123 · cited 1×
“This is aggravated by the lack of novel interventions capable of ameliorating depressive symptoms (Berk et al., 2011; Carvalho et al., 2014), and increasing attention and efforts are being paid to the repurposing of diverse and already developed drugs to psychiatric disorders.”
BackgroundSelf-citationSalagre, E., Fernandes, B. S., Dodd, S., Brownstein, D. J., & Berk, M. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.04.047 · Cited by 117 · cited 2×
“Drugs that decrease inflammation, such as statins (Salagre et al., 2016), celecoxib (Na et al., 2014) and N-acetyl-cysteine (NAC) (Fernandes et al., 2016) have shown beneficial effects on depression at a meta-analytic level of evidence.”
BackgroundSelf-citationApplegate, W. B., Phillips, H. L., Schnaper, H., Shepherd, A. M., Schocken, D., Luhr, J. C., Koch, G. G., & Park, G. D. (1991) · Archives of Internal Medicine · doi:10.1001/archinte.1991.00400090099018 · Cited by 115 · cited 3×
“A placebo washout period (between 4 and 8 weeks) was used in 9 of the studies (Applegate et al., 1991; Croog et al., 1990; Dahlof et al., 1997, 2005; Omvik et al., 1993; Rake et al., 2001; Rasmussen et al., 2006; Steiner et al., 1990).”
MethodN-Acetylcysteine in Depressive Symptoms and Functionality
Fernandes, B. S., Dean, O. M., Dodd, S., Malhi, G. S., & Berk, M. (2016) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.15r09984 · Cited by 108 · cited 2×
“Drugs that decrease inflammation, such as statins (Salagre et al., 2016), celecoxib (Na et al., 2014) and N-acetyl-cysteine (NAC) (Fernandes et al., 2016) have shown beneficial effects on depression at a meta-analytic level of evidence.”
BackgroundSelf-citationKume, K., Hanyu, H., Sakurai, H., Takada, Y., Onuma, T., & Iwamoto, T. (2011) · Geriatrics and gerontology international/Geriatrics & gerontology international · doi:10.1111/j.1447-0594.2011.00746.x · Cited by 104
Ss, S., Friedhoff, A. J., Bl, W., Wecker, J. R., & Jp, S. (1990) · PubMed · Cited by 102
Assessing Publication Bias in Meta-Analysis
Soeken, K. L., & Sripusanapan, A. (2003) · Nursing Research · doi:10.1097/00006199-200301000-00009 · Cited by 94 · cited 1×
“…for verifying publication bias, which is a scatter plot of the SMD against a measure of study size, calculated the Egger test (Egger et al., 1997; Soeken and Sripusanapan, 2003) and employed the Orwin’s fail-safe N test to quantify the number of possible negative omitted studies that would be…”
MethodOmvik, P., Thaulow, E., Herland, O. B., Eide, I. A., Midha, R., & Turner, R. R. (1993) · Journal of Hypertension · doi:10.1097/00004872-199301000-00015 · Cited by 92 · cited 3×
“A placebo washout period (between 4 and 8 weeks) was used in 9 of the studies (Applegate et al., 1991; Croog et al., 1990; Dahlof et al., 1997, 2005; Omvik et al., 1993; Rake et al., 2001; Rasmussen et al., 2006; Steiner et al., 1990).”
MethodQuality of life with three antihypertensive treatments. Cilazapril, atenolol, nifedipine.
Fletcher, A., Bulpitt, C. J., Chase, D. M., Collins, W., Furberg, C. D., Goggin, T. K., HEWETT, A. J., & Neiß, A. (1992) · Hypertension · doi:10.1161/01.hyp.19.6.499 · Cited by 90 · cited 2×
“Twenty studies did not use a validated scale for measuring QoL and were hence excluded (Bracchetti et al., 1990; Conlin et al., 1998; Croog et al., 1986; Ebert and Kirch, 1999; Fagher et al., 1991; Fletcher et al., 1992; Freytag et al., 2001; Hu and Zhu, 1999; Lacourciere, 1988; Lewis et al., 1996; McMahon et al., 199…”
BackgroundMicroglial TNF‐α mediates enhancement of dopaminergic degeneration by brain angiotensin
Borrajo, A., Rodriguez-Perez, A. I., Díaz-Ruiz, C., Guerra, M. J., & Labandeira-García, J. L. (2013) · Glia · doi:10.1002/glia.22595 · Cited by 87 · cited 5×
“Drugs that decrease angiotensin II activity have pleiotropic mechanisms of action that suggest potential efficacy as novel psychotropic agents for neuropsychiatric disorders (Benicky et al., 2011; Borrajo et al., 2014; De Souza et al., 2015; Kume et al., 2012; Li et al., 2010) and neuroprotection (Cernes et al.”
BackgroundMethodInfluentialOparil, S., Barr, E., Elkins, M., Liss, C. L., Vrecenak, A. J., & Edelman, J. M. (1996) · Clinical Therapeutics · doi:10.1016/s0149-2918(96)80212-8 · Cited by 83 · cited 2×
“…Fletcher et al., 1992; Freytag et al., 2001; Hu and Zhu, 1999; Lacourciere, 1988; Lewis et al., 1996; McMahon et al., 1990; Neaton et al., 1993; Oparil et al., 1996; Paran et al., 1996; Perry et al., 1994; Tanser et al., 2000; Tedesco et al., 1999; Testa et al., 1993; Weir et al., 1996a;…”
Ghanizadeh, A., & Hedayati, A. (2013) · Depression and Anxiety · doi:10.1002/da.22195 · Cited by 81 · cited 3×
“Therefore, the quality of the evidence was ‘unclear’ in most situations despite the large sample size of many of these randomized trials (Ghanizadeh and Hedayati, 2013).”
BackgroundMethodInfluentialGu, P., Qian, W., Song, G., & Zhaochun, S. (2014) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2014.05.006 · Cited by 80 · cited 2×
“Drugs that act on the angiotensin system, such as the antihypertensives angiotensin I converting enzyme (ACE) inhibitors and angiotensin II type 1 receptor (AT1R) blockers, have been suggested to possess antidepressive properties (Bortolato et al., 2016; Ping et al., 2014).”
BackgroundHypertensive Black Men and Women
Croog, S. H., Kong, B. W., LEVINE, S. A., Weir, M. R., Baume, R. M., & Saunders, E. (1990) · Archives of Internal Medicine · doi:10.1001/archinte.1990.00040031733024 · Cited by 73 · cited 2×
“A placebo washout period (between 4 and 8 weeks) was used in 9 of the studies (Applegate et al., 1991; Croog et al., 1990; Dahlof et al., 1997, 2005; Omvik et al., 1993; Rake et al., 2001; Rasmussen et al., 2006; Steiner et al., 1990).”
MethodQuality of Life and Antihypertensive Effect With Nebivolol and Losartan
VANBORTEL, L., Bulpitt, C. J., & Fıcı, F. (2005) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2005.03.733 · Cited by 73 · cited 3×
“We additionally excluded 18 studies (Boissel et al., 1995; Breed et al., 1992; Bursztyn et al., 1993; Chan et al., 1997; Croog et al., 1994; Degl’Innocenti et al., 2004; Frimodt-Moeller et al., 1991; Glik et al., 1990; Herrick et al., 1989; Hill et al., 1985; Kundu et al., 1990; Levine et al., 1987, 1995; Malmqvist et…”
BackgroundLewis, C. E. (1996) · Archives of Internal Medicine · doi:10.1001/archinte.1996.00440040047006 · Cited by 71
FLETCHER, A. E., Bulpitt, C. J., Hawkins, C. M., Havinga, T. K., ten Berge, B. S., May, J. F., Schuurman, F. H., van der Veur, E., & Wesseling, H. (1990) · Journal of Hypertension · doi:10.1097/00004872-199005000-00011 · Cited by 70 · cited 1×
“One study (Fletcher et al., 1990) used the Symptom Rating Test (SRT) as a means to assess QoL.”
MethodAncelin, M., Carrière, I., Scali, J., Ritchie, K. A., Chaudieu, I., & Ryan, J. L. (2013) · Translational Psychiatry · doi:10.1038/tp.2013.95 · Cited by 69 · cited 1×
“Polymorphisms of angiotensin genes appear associated with mood and psychotic (Ancelin et al., 2013; Zhang et al., 2014) disorders.”
BackgroundHaghighi, M., Khodakarami, S., Jahangard, L., Ahmadpanah, M., Bajoghli, H., Holsboer-Trachsler, E., & Brand, S. (2014) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2014.07.018 · Cited by 65
Treatment of recurrent unipolar major depression with captopril
Germain, L., & Chouinard, G. (1988) · Biological Psychiatry · doi:10.1016/0006-3223(88)90010-8 · Cited by 63 · cited 2×
“In the early 1980s several case reports revealed that captopril promoted possible mood elevation in patients with unipolar depression (Germain and Chouinard, 1988) and mood benefits also reported with lisinopril (Hertzman et al., 2005).”
BackgroundBias in emerging biomarkers for bipolar disorder
Carvalho, A. F., Köhler, C. A., Fernandes, B. S., Quevedo, J., Miskowiak, K. W., Brunoni, A. R., Machado-Vieira, R., Maes, M., Vieta, E., & Berk, M. (2016) · Psychological Medicine · doi:10.1017/s0033291716000957 · Cited by 63
Self-citationDegl’Innocenti, A., Elmfeldt, D., Albert Hofman, D., Lithell, H., Olofsson, B., Skoog, I. G., Trenkwalder, P., Zanchetti, A., & Wiklund, I. E. (2004) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1001657 · Cited by 62 · cited 1×
“We additionally excluded 18 studies (Boissel et al., 1995; Breed et al., 1992; Bursztyn et al., 1993; Chan et al., 1997; Croog et al., 1994; Degl’Innocenti et al., 2004; Frimodt-Moeller et al., 1991; Glik et al., 1990; Herrick et al., 1989; Hill et al., 1985; Kundu et al., 1990; Levine et al.,…”
BackgroundJohansen, A., Holmen, J., Stewart, R. J., & Bjerkeset, O. A. (2011) · European Journal of Epidemiology · doi:10.1007/s10654-011-9641-y · Cited by 59
Weir, M. R., Elkins, M., Liss, C. L., Vrecenak, A. J., Barr, E., & Edelman, J. M. (1996) · Clinical Therapeutics · doi:10.1016/s0149-2918(96)80022-1 · Cited by 55 · cited 2×
“…al., 1992; Freytag et al., 2001; Hu and Zhu, 1999; Lacourciere, 1988; Lewis et al., 1996; McMahon et al., 1990; Neaton et al., 1993; Oparil et al., 1996; Paran et al., 1996; Perry et al., 1994; Tanser et al., 2000; Tedesco et al., 1999; Testa et al., 1993; Weir et al., 1996a; Yodfat et al., 1985).”
BackgroundDahlöf, B., Lindholm, L. H., Carney, S. L., Pentikäinen, P. J., & Östergren, J. (1997) · Journal of Hypertension · doi:10.1097/00004872-199715110-00018 · Cited by 53 · cited 2×
“A placebo washout period (between 4 and 8 weeks) was used in 9 of the studies (Applegate et al., 1991; Croog et al., 1990; Dahlof et al., 1997, 2005; Omvik et al., 1993; Rake et al., 2001; Rasmussen et al., 2006; Steiner et al., 1990).”
MethodDifferential clinical profile of candesartan compared to other angiotensin receptor blockers
Zimlichman, R. (2011) · Vascular Health and Risk Management · doi:10.2147/vhrm.s22591 · Cited by 53 · cited 1×
“…II activity have pleiotropic mechanisms of action that suggest potential efficacy as novel psychotropic agents for neuropsychiatric disorders (Benicky et al., 2011; Borrajo et al., 2014; De Souza et al., 2015; Kume et al., 2012; Li et al., 2010) and neuroprotection (Cernes et al., 2011).”
BackgroundBias in Peripheral Depression Biomarkers
Carvalho, A. F., Köhler, C. A., Brunoni, A. R., Miskowiak, K. W., Herrmann, N., Lanctôt, K. L., Hyphantis, T. N., Quevedo, J., Fernandes, B. S., & Berk, M. (2016) · Psychotherapy and Psychosomatics · doi:10.1159/000441457 · Cited by 52
Self-citationMalmqvist, K. K., Kahan, T., & Dahl, M. (2000) · American Journal of Hypertension · doi:10.1016/s0895-7061(99)00264-2 · Cited by 49 · cited 2×
“…et al., 2004; Frimodt-Moeller et al., 1991; Glik et al., 1990; Herrick et al., 1989; Hill et al., 1985; Kundu et al., 1990; Levine et al., 1987, 1995; Malmqvist et al., 2000; Os et al., 1991; Van Bortel et al., 2005; Weir et al., 1996b, 2005) due to insufficient data required for this analysis.”
BackgroundEffects of Antihypertensive Medications on Quality of Life in Elderly Hypertensive Women
Croog, S. H., Elias, M. F., Colton, T., Baume, R. M., Leiblum, S. R., Jenkins, C. D., Perry, M., & Hall, W. D. (1994) · American Journal of Hypertension · doi:10.1093/ajh/7.4.329 · Cited by 49 · cited 2×
“We additionally excluded 18 studies (Boissel et al., 1995; Breed et al., 1992; Bursztyn et al., 1993; Chan et al., 1997; Croog et al., 1994; Degl’Innocenti et al., 2004; Frimodt-Moeller et al., 1991; Glik et al., 1990; Herrick et al., 1989; Hill et al., 1985; Kundu et al., 1990; Levine et al.,…”
BackgroundComparison of enalapril and atenolol in mild to moderate hypertension
Herrick, A. L., WALLER, P. C., Berkin, K. E., Pringle, S. D., Callender, J. S., Robertson, M. P., Findlay, J. G., Murray, G. D., Reid, J. L., Lorimer, A. R., et al. (1989) · The American Journal of Medicine · doi:10.1016/0002-9343(89)90340-9 · Cited by 47
Freytag, F., Schelling, A., Meinicke, T., & Deichsel, G. (2001) · Clinical Therapeutics · doi:10.1016/s0149-2918(01)80034-5 · Cited by 42 · cited 2×
“…hence excluded (Bracchetti et al., 1990; Conlin et al., 1998; Croog et al., 1986; Ebert and Kirch, 1999; Fagher et al., 1991; Fletcher et al., 1992; Freytag et al., 2001; Hu and Zhu, 1999; Lacourciere, 1988; Lewis et al., 1996; McMahon et al., 1990; Neaton et al., 1993; Oparil et al., 1996; Paran…”
Background&NA; (1990) · Current Opinion in Rheumatology · doi:10.1097/00002281-199002030-00018 · Cited by 40
Weir, M. R., Ferdinand, K. C., Flack, J. M., Jamerson, K., Daley, W. L., & Zelenkofske, S. L. (2005) · Hypertension · doi:10.1161/01.hyp.0000180457.82483.6b · Cited by 39 · cited 2×
“…et al., 2004; Frimodt-Moeller et al., 1991; Glik et al., 1990; Herrick et al., 1989; Hill et al., 1985; Kundu et al., 1990; Levine et al., 1987, 1995; Malmqvist et al., 2000; Os et al., 1991; Van Bortel et al., 2005; Weir et al., 1996b, 2005) due to insufficient data required for this analysis.”
BackgroundMcCorvey, E., Jt, W., Jp, C., Jm, M., Jd, P., & Mp, A. (1993) · PubMed · Cited by 38
Angiotensin converting enzyme inhibitors and quality of life: the European trial.
Jf, H., Cj, B., & Ae, F. (1985) · PubMed · Cited by 36
Gomes, J. A. D. S., de Souza, G. C., Berk, M., Cavalcante, L. M., de Sousa, F. C. F., Budni, J., de Lucena, D. F., Quevedo, J., Carvalho, A. F., & Macêdo, D. S. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.08.005 · Cited by 34 · cited 3×
“…decrease neuroinflammation by decreasing angiotensin II activity and have therefore been proposed as novel therapeutic targets for inflammatory brain diseases as well as for cognitive disorders (Benicky et al., 2011; Borrajo et al., 2014; De Souza et al., 2015, Kume et al., 2012; Li et al., 2010).”
BackgroundMethodSelf-citationBoissel, J., Collet, J., Lion, L., Ducruet, T., Moleur, P., Luciani, J., Milon, H., Madonna, O., Gillet, J., Gerini, P., et al. (1995) · Journal of Hypertension · doi:10.1097/00004872-199509000-00018 · Cited by 34 · cited 1×
“We additionally excluded 18 studies (Boissel et al., 1995; Breed et al., 1992; Bursztyn et al., 1993; Chan et al., 1997; Croog et al., 1994; Degl’Innocenti et al., 2004; Frimodt-Moeller et al., 1991; Glik et al., 1990; Herrick et al., 1989; Hill et al., 1985; Kundu et al., 1990; Levine et al.,…”
BackgroundKusek, J. W., Lee, J. Y., Smith, D. E., Milligan, S. E., Faulkner, M. L., Cornell, C. E., Kopple, J. D., & Greene, P. G. (1996) · Controlled Clinical Trials · doi:10.1016/s0197-2456(97)82681-5 · Cited by 29
Effects of captopril on opioid peptides during exercise and quality of life in normal subjects
D, K. H. M., Sasaki, J., Tanaka, H., Kiyonaga, A., Matsunaga, A., Shindo, M., & Arakawa, K. (1991) · American Heart Journal · doi:10.1016/0002-8703(91)90582-3 · Cited by 29
Weir, M. (1996) · American Journal of Hypertension · doi:10.1016/s0895-7061(96)00116-1 · Cited by 29 · cited 2×
“…al., 1992; Freytag et al., 2001; Hu and Zhu, 1999; Lacourciere, 1988; Lewis et al., 1996; McMahon et al., 1990; Neaton et al., 1993; Oparil et al., 1996; Paran et al., 1996; Perry et al., 1994; Tanser et al., 2000; Tedesco et al., 1999; Testa et al., 1993; Weir et al., 1996a; Yodfat et al., 1985).”
BackgroundTanser, P. H., Campbell, L. M., Carranza, J., Karrasch, J., Toutouzas, P. K., & Watts, R. W. (2000) · American Journal of Hypertension · doi:10.1016/s0895-7061(99)00165-x · Cited by 29 · cited 1×
“…al., 1992; Freytag et al., 2001; Hu and Zhu, 1999; Lacourciere, 1988; Lewis et al., 1996; McMahon et al., 1990; Neaton et al., 1993; Oparil et al., 1996; Paran et al., 1996; Perry et al., 1994; Tanser et al., 2000; Tedesco et al., 1999; Testa et al., 1993; Weir et al., 1996a; Yodfat et al., 1985).”
Lisinopril May Augment Antidepressant Response
Hertzman, M., Adler, L., Arling, B., & Kern, M. (2005) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000186736.99523.1d · Cited by 27
Quality of life in hypertensives treated with atenolol or captopril: a double-blind crossover trial
Palmer, A. J., FLETCHER, A. E., Rudge, P. J., Andrews, C. D., Callaghan, T. S., & Bulpitt, C. J. (1992) · Journal of Hypertension · doi:10.1097/00004872-199211000-00014 · Cited by 27 · cited 2×
“…Marques et al., 2015), four studies were crossover randomized control trials (Dahlof and Dimenas, 1992; Handa et al., 1991; McCorvey et al., 1993; Palmer et al., 1992), and five studies were not available in English (Andreeva et al., 2004; Carre et al., 1988; Gralec et al., 1997; Metelitsa et…”
BackgroundFrimodt-Moeller, J., Poulsen, D. L., Kornerup, H. J., & Bech, P. (1991) · PubMed · Cited by 26
Paran, E., Anson, O., & Neumann, L. (1996) · American Journal of Hypertension · doi:10.1016/s0895-7061(96)00253-1 · Cited by 26
da Silva, P. M., Haag, U., Guest, J. F., Brazier, J. E., & Soro, M. (2015) · Health and Quality of Life Outcomes · doi:10.1186/s12955-015-0216-6 · Cited by 26 · cited 2×
“Three studies analysed drugs that decrease angiotensin activity in both arms (Breeze et al., 2001; Chien et al., 2002; Marques et al., 2015), four studies were crossover randomized control trials (Dahlof and Dimenas, 1992; Handa et al., 1991; McCorvey et al., 1993; Palmer et al., 1992), and five…”
BackgroundQuality of Life in Hypertensive Patients Treated with Either Carvedilol or Enalapril
Östergren, J., Storstein, L., Karlberg, B. E., & Tibblin, G. (1996) · Blood Pressure · doi:10.3109/08037059609062105 · Cited by 25 · cited 1×
“One study was excluded as it employed a scale that assessed a purely physical domain of QoL (Ostergren et al., 1996).”
BackgroundConlin, P. R., Elkins, M., Liss, C. L., Vrecenak, A. J., Barr, E., & Edelman, J. (1998) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1000687 · Cited by 24 · cited 2×
“Twenty studies did not use a validated scale for measuring QoL and were hence excluded (Bracchetti et al., 1990; Conlin et al., 1998; Croog et al., 1986; Ebert and Kirch, 1999; Fagher et al., 1991; Fletcher et al., 1992; Freytag et al., 2001; Hu and Zhu, 1999; Lacourciere, 1988; Lewis et al., 1996; McMahon et al., 199…”
MethodAdditive effects of verapamil and enalapril in the treatment of mild to moderate hypertension
LEVINE, J., Ferdinand, K. C., Cargo, P., Laine, H., & Lefkowitz, M. P. (1995) · American Journal of Hypertension · doi:10.1016/0895-7061(95)00053-r · Cited by 23 · cited 1×
“…al., 1994; Degl’Innocenti et al., 2004; Frimodt-Moeller et al., 1991; Glik et al., 1990; Herrick et al., 1989; Hill et al., 1985; Kundu et al., 1990; Levine et al., 1987, 1995; Malmqvist et al., 2000; Os et al., 1991; Van Bortel et al., 2005; Weir et al., 1996b, 2005) due to insufficient data…”
Efficacy and safety of atenolol, enalapril, and isradipine in elderly hypertensive women
Perry, H. M., Hall, W. D., Benz, J. R., Bartels, D. W., Kostis, J. B., Townsend, R. R., Due, D. L., Peng, A., & Sirgo, M. A. (1994) · The American Journal of Medicine · doi:10.1016/0002-9343(94)90118-x · Cited by 21 · cited 2×
“…al., 1992; Freytag et al., 2001; Hu and Zhu, 1999; Lacourciere, 1988; Lewis et al., 1996; McMahon et al., 1990; Neaton et al., 1993; Oparil et al., 1996; Paran et al., 1996; Perry et al., 1994; Tanser et al., 2000; Tedesco et al., 1999; Testa et al., 1993; Weir et al., 1996a; Yodfat et al., 1985).”
Angiotensin Converting Enzyme Inhibitors and Risk of Mood Disorders
Williams, L. J., Pasco, J. A., Kessing, L. V., Quirk, S. E., Fernandes, B. S., & Berk, M. (2016) · Psychotherapy and Psychosomatics · doi:10.1159/000444646 · Cited by 21 · cited 2×
“More recently, in a 5-year follow-up from the Geelong Osteoporosis Study (GOS), the incidence of a first episode of depression was 5.3% in men with no use of ACE inhibitors, and zero on those on ACE inhibitors (Williams et al., 2016).”
BackgroundInfluentialSelf-citationA double-blind comparison of transdermal clonidine and oral captopril in essential hypertension.
McMahon, F. G., Jain, A. K., Vargas, R., & Fillingim, J. M. (1990) · PubMed · Cited by 20
Dahlöf, B., Degl’Innocenti, A., Elmfeldt, D., PUIG, J., GUNDERSEN, T., Hosie, J., Januszewicź, W., LINDSTROM, C., Magometschnigg, D., & Tanser, P. H. (2005) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2005.04.017 · Cited by 19 · cited 2×
“A placebo washout period (between 4 and 8 weeks) was used in 9 of the studies (Applegate et al., 1991; Croog et al., 1990; Dahlof et al., 1997, 2005; Omvik et al., 1993; Rake et al., 2001; Rasmussen et al., 2006; Steiner et al., 1990).”
MethodWilliams, S. A., Michelson, E. L., Cain, V. A., Yang, M. S., Nesbitt, S. D., Egan, B. M., & Julius, S. (2008) · Journal of Clinical Hypertension · doi:10.1111/j.1751-7176.2008.07837.x · Cited by 18 · cited 2×
“The SF-36 has been documented as both valid and reliable (Mchorney et al., 1994; Russo et al., 1998), and was used in two studies (Kusek et al., 1996; Williams et al., 2008).”
MethodChan, P., Lin, C. N., Tomlinson, B., Lin, T. H., & Lee, Y. S. (1997) · American Journal of Hypertension · doi:10.1016/s0895-7061(96)00060-x · Cited by 18 · cited 2×
“We additionally excluded 18 studies (Boissel et al., 1995; Breed et al., 1992; Bursztyn et al., 1993; Chan et al., 1997; Croog et al., 1994; Degl’Innocenti et al., 2004; Frimodt-Moeller et al., 1991; Glik et al., 1990; Herrick et al., 1989; Hill et al., 1985; Kundu et al., 1990; Levine et al.,…”
BackgroundEffects of antihypertensive medications on vitality and well-being.
Levine, S., Croog, S. H., Sudilovsky, A., & Testa, M. A. (1987) · PubMed · Cited by 17
COHEN, L., Anderson, G., White, R. F., Griffing, G. T., & Melby, J. C. (1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.8.1012 · Cited by 17 · cited 1×
“Their antidepressant effects can be further inferred by mood elation in healthy volunteers taking enalapril (Cohen et al., 1984).”
BackgroundRake, E., Breeze, E., & Fletcher, A. (2001) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1001283 · Cited by 15 · cited 3×
“A placebo washout period (between 4 and 8 weeks) was used in 9 of the studies (Applegate et al., 1991; Croog et al., 1990; Dahlof et al., 1997, 2005; Omvik et al., 1993; Rake et al., 2001; Rasmussen et al., 2006; Steiner et al., 1990).”
MethodBreed, J. G. S., Ciampricotti, R., Tromp, G. P., Valster, F., Lageweg, E., & Bortel, L. M. V. (1992) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-199211000-00010 · Cited by 15
Jacobsen, J. R., & Poulsen, K. (1985) · Journal of Hypertension · doi:10.1097/00004872-198504000-00008 · Cited by 14
Lacourcière, Y. (1988) · The American Journal of Medicine · doi:10.1016/s0002-9343(88)91089-3 · Cited by 13
Breeze, E., Rake, E., Donoghue, M., & Fletcher, A. (2001) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1001282 · Cited by 13 · cited 2×
“Three studies analysed drugs that decrease angiotensin activity in both arms (Breeze et al., 2001; Chien et al., 2002; Marques et al., 2015), four studies were crossover randomized control trials (Dahlof and Dimenas, 1992; Handa et al., 1991; McCorvey et al., 1993; Palmer et al., 1992), and five…”
BackgroundEbert, U., & Kirch, W. (1999) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050625 · Cited by 9 · cited 2×
“…studies did not use a validated scale for measuring QoL and were hence excluded (Bracchetti et al., 1990; Conlin et al., 1998; Croog et al., 1986; Ebert and Kirch, 1999; Fagher et al., 1991; Fletcher et al., 1992; Freytag et al., 2001; Hu and Zhu, 1999; Lacourciere, 1988; Lewis et al., 1996;…”
MethodCaptopril as a replacement for multiple therapy in hypertension: a controlled study.
Yodfat, Y., Fidel, J., & Bloom, D. S. (1985) · PubMed · Cited by 9
Antihypertensive regimen and quality of life in a disadvantaged population.
Glik, D. C., Steadman, M. S., Michels, P. J., & Mallin, R. (1990) · PubMed · Cited by 8
Chien, K., Huang, P.-J., Chen, M.-F., Chiang, F., Lai, L., & Lee, Y. (2002) · Cardiovascular Drugs and Therapy · doi:10.1023/a:1020648405680 · Cited by 8 · cited 2×
“Three studies analysed drugs that decrease angiotensin activity in both arms (Breeze et al., 2001; Chien et al., 2002; Marques et al., 2015), four studies were crossover randomized control trials (Dahlof and Dimenas, 1992; Handa et al., 1991; McCorvey et al., 1993; Palmer et al., 1992), and five…”
BackgroundBracchetti, D., Gradnik, R., Alberti, A. B., Brunelli, A., Orselli, L., Leonardi, G., Pavesi, P. C., & Cantelli, I. (1990) · Cardiovascular Drugs and Therapy · doi:10.1007/bf01857642 · Cited by 7 · cited 2×
“Twenty studies did not use a validated scale for measuring QoL and were hence excluded (Bracchetti et al., 1990; Conlin et al., 1998; Croog et al., 1986; Ebert and Kirch, 1999; Fagher et al., 1991; Fletcher et al., 1992; Freytag et al., 2001; Hu and Zhu, 1999; Lacourciere, 1988; Lewis et al., 1996; McMahon et al., 199…”
MethodComparison of Verapamil and Captopril in Elderly Hypertensive Subjects
Bursztyn, M., Ghanem, J., Kobrin, I., Fidel, J., & Ben‐Ishay, D. (1993) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-199301000-00012 · Cited by 7 · cited 2×
“We additionally excluded 18 studies (Boissel et al., 1995; Breed et al., 1992; Bursztyn et al., 1993; Chan et al., 1997; Croog et al., 1994; Degl’Innocenti et al., 2004; Frimodt-Moeller et al., 1991; Glik et al., 1990; Herrick et al., 1989; Hill et al., 1985; Kundu et al., 1990; Levine et al.,…”
BackgroundDahlöf, C. G. H., & Dimenäs, E. (1992) · European Journal of Clinical Pharmacology · doi:10.1007/bf02220612 · Cited by 6 · cited 2×
“, 2015), four studies were crossover randomized control trials (Dahlof and Dimenas, 1992; Handa et al., 1991; McCorvey et al., 1993; Palmer et al., 1992), and five studies were not available in English (Andreeva et al.”
BackgroundFagher, B., Katzman, P., Hulthén, U. L., Henningsen, N. C., & Thulin, T. (1991) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.1991.tb00434.x · Cited by 6 · cited 2×
“…validated scale for measuring QoL and were hence excluded (Bracchetti et al., 1990; Conlin et al., 1998; Croog et al., 1986; Ebert and Kirch, 1999; Fagher et al., 1991; Fletcher et al., 1992; Freytag et al., 2001; Hu and Zhu, 1999; Lacourciere, 1988; Lewis et al., 1996; McMahon et al., 1990;…”
BackgroundRasmussen, S., Borrild, N. J., & Andersen, J. (2006) · Clinical Drug Investigation · doi:10.2165/00044011-200626020-00004 · Cited by 5
Zhang, G., Zhang, F., Zhu, J., Zhang, F., Yuan, J., Xue, Z., & Jin, C. (2014) · Psychiatry Research · doi:10.1016/j.psychres.2014.08.027 · Cited by 5 · cited 1×
“Polymorphisms of angiotensin genes appear associated with mood and psychotic (Ancelin et al., 2013; Zhang et al., 2014) disorders.”
BackgroundSiegrist, J., Middeke, M., & Osterkorn, K. (1991) · PubMed · Cited by 5
Hu, Y., & Zhu, J. (1999) · PubMed · Cited by 4
胡予, & 诸骏仁 (1999) · 中华医学杂志:英文版 · Cited by 3
Ramipril and methyldopa compared in patients with mild to moderate hypertension.
Kundu, S. C., Bhattacharya, A., & Vakil, H. B. (1991) · PubMed · Cited by 3
Фатиховна, А. Г., Gorbunov, V. M., Ta, A., Isaĭkina, O. I., Vp, V., & Lerman, O. V. (2004) · PubMed · Cited by 3
Carre, A. G., Petetin, N., Jouvent, R., Baruch, P., d’Allens, H., & Pappo, M. (1988) · La Revue de Médecine Interne · doi:10.1016/s0248-8663(88)80023-7 · Cited by 2 · cited 1×
“…were crossover randomized control trials (Dahlof and Dimenas, 1992; Handa et al., 1991; McCorvey et al., 1993; Palmer et al., 1992), and five studies were not available in English (Andreeva et al., 2004; Carre et al., 1988; Gralec et al., 1997; Metelitsa et al., 1996; Siegrist et al., 1991).”
Background[Changes in the quality of life influenced by treatment of primary arterial hypertension].
Gralec, M., Piusińska-Macoch, A., Cholewa, M., & Sułek, K. (1997) · PubMed · Cited by 1
Metelitsa, V. I., Sg, D., Tp, O., Np, F., Gf, M., Vygodin, V. A., Broer, M., & Siegrist, I. (1996) · PubMed · Cited by 1
Research works printed but not linked: 5
- Carre A, Petetin N, Jouvent R, et al. (1988) Blood pressure control and quality of life: A comparative multicenter double-blind and cross-over trial of labetalol and captopril. La Revue de Médecine Interne 9: 545–553.
- Higgins JPT, Green S (2011) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. London: The Cochrane Collaboration.
- Jp H (2011) Handbook for Systematic Reviews of Interventions Version 5.1.0. London: The Cochrane Collaboration.
- 10.1001/jama.1993.03510060059034 · DOI · Paper page
- Os I, Bratland B, Dahlof B, et al. (1991) Lisinopril and nifedipine in essential hypertension: A Norwegian multicenter study on efficacy, tolerability and quality of life in 828 patients. Journal of Hypertension 9: S382–S383.
Cited by
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Bond, D. J., Frey, B. N., Sharma, V., Goldstein, B. I., Rej, S., Beaulieu, S., et al. (2018) · Bipolar Disorders · doi:10.1111/bdi.12609 · Cited by 1,852
Self-citationGoldstein, B. I., Baune, B. T., Bond, D. J., Chen, P., Eyler, L. T., Fagiolini, A. M., Gomes, F. A., Hájek, T., Hatch, J. K., McElroy, S. L., et al. (2020) · Bipolar Disorders · doi:10.1111/bdi.12921 · Cited by 121
Antihypertensive Drugs and Risk of Depression: A Nationwide Population-Based Study
Kessing, L. V., Rytgaard, H. C. W., Ekstrøm, C. T., Torp-Pedersen, C. T., Berk, M., & Gerds, T. A. (2020) · Hypertension · doi:10.1161/hypertensionaha.120.15605 · Cited by 107
“Use of ACE inhibitors and ARBs for the treatment of hypertension in otherwise healthy adults has been associated with improved mental health domains of quality of life.(21) There are no randomized clinical trials of angiotensin agents and depression.”
MethodSelf-citationCarnovale, C., Perrotta, C., Baldelli, S., Cattaneo, D., Montrasio, C., Barbieri, S. S., Pompilio, G., Vantaggiato, C., Clementi, E., & Pozzi, M. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac110 · Cited by 70
“ther placebo or non-ACEI or non-ARBs, the use of ACEI or ARBs was significantly associated with improved mental health domains in adults (overall quality of life, positive wellbeing, mental and anxiety domains of quality of life).(104) Noteworthy, in a recent 12-week randomized, double-blind, placebocontrolled study,…”
ResultRole of brain renin–angiotensin system in depression: A new perspective
Ali, N. H., Al-Kuraishy, H. M., Al-Gareeb, A. I., Albuhadily, A. K., Hamad, R. S., Alexiou, A. T., Papadakis, M., Saad, H. M., & Batiha, G. E. (2023) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.14525 · Cited by 55
“103 It has been shown that ACEIs and ARBs reduce the use of antidepressant drugs in hypertensive patients with depression.”
Background
Metadata
- Authors
- Brownstein, D. J., Salagre, E., Köhler, C., Stubbs, B., Vian, J., Pereira, C., Chavarria, V., Karmakar, C., Turner, A., Quevedo, J., Carvalho, A. F., Berk, M., & Fernandes, B. S.
- Affiliations
- Monash University (AU)
- Centro de Investigación Biomédica en Red de Salud Mental (ES)
- Universidade Federal do Ceará (BR)
- King's College London (GB)
- University of Lisbon (PT)
- Parc de Salut (ES)
- Deakin University (AU)
- Barwon Health (AU)
- The University of Texas MD Anderson Cancer Center (US)
- Translational Psychiatry Research Group and Department of Clinical Medicine, Faculty of Medicine, Federal University of Ceará, Fortaleza, Brazil
- Universidade Federal do Rio Grande do Sul (BR)
- Corresponding author
- Fernandes, Brisa S
- ORCID
- Venue
- Australian & New Zealand Journal of Psychiatry
- Publisher
- SAGE Publications
- Published
- 2017-07-28
- Volume
- 52
- Issue
- 1
- Pages
- 24-38
- ISSN
- 0004-8674 (ISSN-L)
- 1440-1614
- OpenAlex
- W2740997385
- Cited by
- 46
- References
- 116
- Citations by year
- 2026: 4 · 2025: 6 · 2024: 2 · 2023: 6 · 2022: 10 · 2021: 4 · 2020: 8 · 2019: 1 · 2018: 5
- FWCI
- 0.54
- Type
- journal article
- Language
- en
- Open access
- green
- figshare.com
- Licence
- cc-by
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Australian & New Zealand Journal of Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Own your potential (DEAKIN) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) (submittedVersion)
- Funders
- National Institute for Health and Care Research (ICA-CL-2017-03-001, NIHR-INF-0685)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac Health and Mental Health
- Keywords
- ACE inhibitors, angiotensin receptor blockers, quality of life, mental health, well-being, anxiety, depression, hypertension, antihypertensive drugs, psychiatric adverse effects
- MeSH terms
- Angiotensin-Converting Enzyme Inhibitors, Anxiety, Humans, Hypertension, Mental Health, Quality of Life, Randomized Controlled Trials as Topic, Angiotensin II Type 1 Receptor Blockers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.